Segment and Geographic Information

12 Months Ended

Jun. 27, 2015

Segments and Geographic Information [Abstract]

Segment and Geographic Information

SEGMENT AND GEOGRAPHIC INFORMATION

As discussed in Note 1, in conjunction with the Omega acquisition, we changed our reporting segments to better align with our new organizational structure. This structure is consistent with the way our chief operating decision maker makes operating decisions, allocates resources and manages the growth and profitability of the business. Operating segments with similar economic characteristics, including long-term profitability, nature of the products sold and production processes, distribution methods, and classes of customers, are aggregated as reportable segments.

We generated third-party net sales in the following geographic locations⁽¹⁾ during each of the fiscal years presented (in millions):

	2015		2014		2013
Ireland	$	344.0	$	146.7	$	—
U.S.	3,303.6		3,291.6		2,978.1
Europe	613.6		217.2		164.0
All other countries (2)	342.7		405.3		397.7
	$	4,603.9	$	4,060.8	$	3,539.8

⁽¹⁾We attribute net sales to countries based on sales location.

⁽²⁾Includes sales generated primarily in Israel, Mexico, Australia, and Canada.

The net book value of property and equipment at June 27, 2015 and June 28, 2014 was as follows (in millions):

	June 27, 2015		June 28, 2014
Ireland	$	1.4	$	2.0
U.S.	558.6		530.7
Europe	153.8		31.7
Israel	119.8		119.6
All other countries	98.8		95.9
	$	932.4	$	779.9

Sales to Walmart accounted for 15% of consolidated net sales in fiscal year 2015 and 19% in both fiscal year 2014 and fiscal year 2013. Sales to Walmart are reported primarily in our CHC segment.

Below is a summary of our results by reporting segment for fiscal years 2015, 2014, and 2013. Prior periods have been restated to conform to our new reporting segments (in millions).

	CHC			BCH (1)			Rx Pharmaceut-icals			Specialty Sciences (2)			Other			Unallocated expenses			Total (3)
Fiscal Year 2015
Net sales	$	2,750.0		$	401.1		$	1,001.1		$	344.0		$	107.7		$	—		$	4,603.9
Operating income (loss)	$	405.6		$	26.6		$	373.9		$	36.3		$	26.8		$	(121.5	)	$	747.7
Operating income %	14.7		%	6.6		%	37.3		%	10.6		%	24.9		%	—		%	16.2		%
Total assets	$	4,381.6		$	6,441.1		$	2,667.9		$	5,979.0		$	251.0		$	—		$	19,720.6
Capital expenditures	$	80.5		$	3.6		$	42.9		$	0.5		$	6.4		$	3.1		$	137.0
Property and equip, net	$	600.0		$	122.5		$	124.1		$	—		$	85.8		$	—		$	932.4
Depreciation/amortization	$	123.2		$	38.3		$	85.1		$	291.6		$	10.6		$	—		$	548.8
Fiscal Year 2014
Net sales	$	2,849.4		$	—		$	927.1		$	146.7		$	137.6		$	—		$	4,060.8
Operating income (loss)	$	413.1		$	—		$	349.8		$	(68.6	)	$	46.1		$	(173.4	)	$	567.0
Operating income (loss) %	14.5		%	—		%	37.7		%	(46.7		)%	33.5		%	—		%	14.0		%
Total assets	$	4,931.0		$	—		$	2,537.2		$	6,096.6		$	288.0		$	—		$	13,852.8
Capital expenditures	$	128.3		$	—		$	32.9		$	—		$	10.4		$	—		$	171.6
Property and equip, net	$	577.3		$	—		$	104.8		$	2.1		$	95.7		$	—		$	779.9
Depreciation/amortization	$	106.6		$	—		$	86.5		154.4			$	11.4		$	—		$	358.9
Fiscal Year 2013
Net sales	$	2,671.0		$	—		$	709.5		—			$	159.3		$	—		$	3,539.8
Operating income (loss)	$	401.8		$	—		$	263.2		—			$	48.9		$	(34.7	)	$	679.1
Operating income %	15.0		%	—		%	37.1		%	—		%	30.7		%	—		%	19.2		%
Total assets	$	3,447.5		$	—		$	1,604.9		—			$	284.5		$	—		$	5,336.9
Capital expenditures	$	97.1		$	—		$	17.7		—			$	17.3		$	—		$	132.2
Property and equip, net	$	508.0		$	—		$	80.8		—			$	92.7		$	—		$	681.4
Depreciation/amortization	$	96.1		$	—		$	54.9		—			$	9.1		$	—		$	160.2

⁽¹⁾    BCH only includes activity from March 30, 2015 to June 27, 2015.

⁽²⁾    Specialty Sciences only includes activity from December 18, 2013 to June 28, 2014 for fiscal year 2014.

⁽³⁾Amounts may not cross-foot due to rounding.

The following is a summary of our net sales by category by fiscal year (in millions):

	2015		2014		2013
CHC
Cough/Cold/Allergy/Sinus (1)	$	486.2	$	510.1	$	500.6
Analgesics (1)	441.7		504.0		536.0
Gastrointestinal (1)	395.3		400.1		388.8
Infant nutritionals	383.9		374.8		350.1
Smoking cessation	299.4		236.8		193.2
Vitamins, minerals and dietary supplements	185.6		176.9		158.3
Animal health	156.9		178.0		123.2
Other CHC (1), (2)	335.9		468.7		420.9
Total CHC	2,684.9		2,849.4		2,671.1
BCH branded OTC products	401.2		—		—
Generic prescription drugs	1,066.1		927.1		709.5
Tysabri® royalties	344.0		146.7		—
Active pharmaceutical ingredients	107.7		137.6		159.3
Total net sales	$	4,603.9	$	4,060.8	$	3,539.8

⁽¹⁾Includes sales from our OTC contract manufacturing business.

⁽²⁾  Consists primarily of feminine hygiene, diabetes care, dermatological care, diagnostic products, and other miscellaneous or otherwise uncategorized product lines and markets none of which is greater than 10% of the CHC segment.